Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody

M HondaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, JapanCorrespondence[email protected]
View further author information

M MoriyamaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, JapanView further author information

M KondoDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, JapanView further author information

S KumakuraDepartment of Medical Education and Research, Shimane University Faculty of Medicine, Izumo, JapanView further author information

Y SumitaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, JapanView further author information

Y MurakawaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, JapanView further author information

Click to increase image sizeClick to decrease image size

Disclosure statement

MH has received speaking fees from Asahi Kasei Pharma Corporation and Ono Pharmaceutical Co., Ltd. MM has received speaking fees from Mitsubishi-Tanabe Pharma Corporation and Janssen Pharmaceutical KK, and manuscript fees from Sanofi KK. MK has received speaking fees from Eisai Co. Ltd, Chugai Pharma Co. Ltd, Mitsubishi-Tanabe Pharma, Bristol-Myers Squibb, Janssen Pharma KK, Astellas Pharma Inc, Takeda Pharma Co., Nippon Kayaku Co. Ltd, Daiichi-Sankyo Co. Ltd, Asahi Kasei Pharma Co., and AbbVie Japan. SK and YS have no conflicts of interest. YM has received grants from Asahi Kasei Pharmaceutical Co. Ltd, Chugai Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd, Daiichi-Sankyo Co. Ltd, Teijin Pharma Ltd, Eisai Co. Ltd, Nippon Kayaku Co. Ltd, and Mitsubishi-Tanabe Pharma Corporation, instructor fees from Asahi Kasei Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co. Ltd, and Janssen Pharmaceutical KK Eisai Co. Ltd, and speaking fees from Ono Pharmaceutical Co. Ltd, Mitsubishi-Tanabe Pharma Corporation, Astellas Pharma Inc, UCB Japan Co. Ltd, Chugai Pharmaceutical Co. Ltd, AbbVie Japan, Daiichi-Sankyo Co. Ltd, AYUMI Pharmaceutical Corporation, Janssen Pharmaceutical KK, Takeda Pharmaceutical Co. Ltd, Sanofi KK, Teijin Pharma Ltd, Eli Lilly Japan KK, and Eisai Co. Ltd.

Additional information

Funding

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody

Information for

Open access

Opportunities

Help and information

Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature